Marker Therapeutics (NasdaqCM:MRKR) FY Conference Transcript

Summary of Marker Therapeutics FY Conference Call Company Overview - Company: Marker Therapeutics (NasdaqCM:MRKR) - Focus: Immuno-oncology, specifically T-cell therapies using the MAR-T platform - Lead Program: MT-601, targeting relapse lymphoma and expanding into solid tumors [1][2] Core Technology and Differentiation - Technology: MAR-T cells, a first-in-class technology that does not require genetic modification and can target multiple antigens [2][3] - Safety Profile: Excellent safety with no observed ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) or HLH (Hemophagocytic Lymphohistiocytosis), and low-level CRS (Cytokine Release Syndrome) limited to fever [4][13] - Manufacturing Process: Simplified and efficient, with a current vein-to-vein time of 22 days, expected to reduce to 17 days [5][7] Clinical Data and Efficacy - Response Rates: - Non-Hodgkin lymphoma: Overall response rate of 66%, complete response rate of 50% [10] - Hodgkin lymphoma: Overall response rate of 78% [12] - Patient Demographics: Patients heavily pretreated and refractory to multiple lines of treatment, including CAR T cells [10][12] - Durability of Responses: Some patients have surpassed one year of follow-up, with sustained responses noted [10][11] Financial and Market Position - Funding: Received over $30 million from government sources, providing a non-dilutive capital runway [4][17] - Market Opportunity: Potential market for LBCL (Large B-cell Lymphoma) after CAR T-cell treatment could exceed $3 billion by 2030 [14] Future Plans and Milestones - Clinical Trials: Advancing MT-601 into a pivotal single-arm phase 2b study for lymphoma, with plans to enroll patients in pancreatic cancer [8][15] - Upcoming Milestones: Completion of tech transfer to a new CDMO (Contract Development and Manufacturing Organization) and additional patient readouts expected [17] Industry Sentiment and Challenges - Market Sentiment: General cold sentiment towards cell therapy and CAR T cells due to complexities and limitations [19][20] - Strategic Positioning: Marker Therapeutics aims to differentiate itself by addressing the limitations of existing CAR T technologies, focusing on a simpler manufacturing process and broader applicability beyond CD19-targeted therapies [20][21] Conclusion - Marker Therapeutics is positioned to leverage its unique MAR-T technology to address significant unmet medical needs in oncology, with promising clinical data and a clear path towards market entry. The company is focused on advancing its lead asset, MT-601, while exploring opportunities in solid tumors and off-the-shelf therapies.